Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study.
Solomon BJ, Liu G, Felip E, Mok TSK, Soo RA, Mazieres J, Shaw AT, de Marinis F, Goto Y, Wu YL, Kim DW, Martini JF, Messina R, Paolini J, Polli A, Thomaidou D, Toffalorio F, Bauer TM.
Solomon BJ, et al.
J Clin Oncol. 2024 May 31:JCO2400581. doi: 10.1200/JCO.24.00581. Online ahead of print.
J Clin Oncol. 2024.
PMID: 38819031